{
    "nct_id": "NCT02942290",
    "official_title": "A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-NaÃ¯ve Higher-Risk Myelodysplastic Syndromes (MDS)",
    "inclusion_criteria": "* Participant must have documented diagnosis of untreated de novo MDS with:\n\n  * International Prognostic Scoring System (IPSS) risk categories Int-2 or High (minimum IPSS overall score of 1.5) OR Revised IPSS (IPSS-R) categories intermediate, high or very high (score of > 3) and\n  * Presence of less than 20% bone marrow blasts per bone marrow biopsy/aspirate.\n* Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participant has received prior therapy for MDS. (Prior supportive care in form of transfusions or growth factors, etc., is not considered prior therapy).\n* Participant has received prior therapy with a BCL-2 Homology 3 (BH3) mimetic.\n* Participant has a diagnosis other than previously untreated de novo MDS (as defined in the protocol) including:\n\n  * MDS with IPSS risk categories Low or Int-1 (overall IPSS score < 1.5)\n  * Therapy-related MDS (t-MDS).\n  * MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).\n  * MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.\n* Participant has received allogeneic Hematopoietic Stem Cell Transplantation (HSCT) or solid organ transplantation.\n* Participant has received a live attenuated vaccine within 4 weeks prior to the first dose of study drug.",
    "miscellaneous_criteria": ""
}